相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
Igal Rosenstein et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
Pascal Benkert et al.
LANCET NEUROLOGY (2022)
Smouldering multiple sclerosis: the 'real MS'
Gavin Giovannoni et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2022)
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring
Peter A. Calabresi et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis
Maria Trojano et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
Undine Proschmann et al.
FRONTIERS IN NEUROLOGY (2021)
Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis
Pietro Maggi et al.
NEUROLOGY (2021)
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
Helmut Butzkueven et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Marinella Clerico et al.
NEUROTHERAPEUTICS (2020)
Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Benedicte Delcoigne et al.
NEUROLOGY (2020)
Serum neurofilament light levels in normal aging and their association with morphologic brain changes
Michael Khalil et al.
NATURE COMMUNICATIONS (2020)
Sural nerve biopsy: current role and comparison with serum neurofilament light chain levels
Sara Mariotto et al.
JOURNAL OF NEUROLOGY (2020)
Personalized extended interval dosing of natalizumab in MS A prospective multicenter trial
Zoe L. E. van Kempen et al.
NEUROLOGY (2020)
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis
Clara Grazia Chisari et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS
L. Novakova et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo
Martina Absinta et al.
JAMA NEUROLOGY (2019)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson et al.
LANCET NEUROLOGY (2018)
Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
M. Vagberg et al.
ACTA NEUROLOGICA SCANDINAVICA (2017)
The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis
Jan Lycke et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis
Kumar Kandadi Muralidharan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
Pei-Ran Ho et al.
LANCET NEUROLOGY (2017)
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
Tatiana Plavina et al.
NEUROLOGY (2017)
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Lenka Novakova et al.
NEUROLOGY (2017)
α4-integrin receptor desaturation and disease activity return after natalizumab cessation
Tobias Derfuss et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
Jens Kuhle et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Extended interval dosing of natalizumab in multiple sclerosis
L. Zhovtis Ryerson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE
Michael Kaufman et al.
JOURNAL OF NEUROLOGY (2015)
Extended interval dosing of natalizumab: a two-center, 7-year experience
Roberto Bomprezzi et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)
A Primer on Quantitized Data Analysis and Permutation Testing
Dave S. Collingridge
JOURNAL OF MIXED METHODS RESEARCH (2013)
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Martin Gunnarsson et al.
ANNALS OF NEUROLOGY (2011)
Assessing inter-rater reliability when the raters are fixed: Two concepts and two estimates
Valentin Rousson
BIOMETRICAL JOURNAL (2011)
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
P. W. O'Connor et al.
NEUROLOGY (2011)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Neurofilament and glial fibrillary acidic protein in multiple sclerosis
N Norgren et al.
NEUROLOGY (2004)
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
C Malmeström et al.
NEUROLOGY (2003)
Can the expanded disability status scale be assessed by telephone?
J Lechner-Scott et al.
MULTIPLE SCLEROSIS (2003)
分享论文
